MVASI

Manufacturer:

Amgen

Name:

MVASI

HCPCS Code Descriptor:

Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg

Category:

Q Code

HCPCS:

Q5107

NDC(s):

55513-0207-01, 55513-0206-01

Primary Type:

Oncology Biosimilar

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

MVASI is an Oncology Biosimilar drug manufactured by Amgen and administered via the Intravenous route of administration. The Q Code: Q5107 is aligned to the drug MVASI.

Mvasi (bevacizumab) is a cancer drug that blocks the VEGF protein. This medication is used to treat certain cancers of the brain, kidney, liver, lung, colon, rectum, cervix, ovary, or Fallopian tube. Mvasi can also be used to treat specific cancers that affect the membrane lining of the patient’s internal organs. This medication is manufactured by Amgen USA and is biosimilar to Avastin (J9035). Mvasi only has one HCPCS code, Q5107 that was aligned to the medication January 2019. Patient assistance programs for this durg can be found through the Amgen Safety Net Foundation and the Amgen Support Plus program.